Scientific article

Dépistage du cancer de la prostate: utilité, buts et perspectives en 2010

Published inRevue médicale suisse, vol. 6, no. 274, p. 2336-2339
Publication date2010

According to recent results of a sub-group of 20,000 patients from the ERSPC study, prostate cancer screening significantly increases disease specific survival for men with a life expectancy of 15 years. However presently, only 20% of prostate biopsies lead to the diagnosis of cancer. This low yield may be increased by using new tools on their way to validation, such as the blood and urinary markers p2-PSA and PCA3, so as MRI and tridimensional computerized echography. Finally, the tumours detected must be managed with subtlety, since a third of them are not overtly aggressive clinically. Hence, a significant proportion of such tumours may not need immediate curative intent treatment, and can be followed up in an active surveillance protocol.

  • Humans
  • Male
  • Mass Screening/methods
  • Prostatic Neoplasms/diagnosis/prevention & control
Citation (ISO format)
ISELIN, Christophe, JICHLINSKI, Patrice. Dépistage du cancer de la prostate: utilité, buts et perspectives en 2010. In: Revue médicale suisse, 2010, vol. 6, n° 274, p. 2336–2339.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation10/17/2013 2:48:00 PM
First validation10/17/2013 2:48:00 PM
Update time03/14/2023 8:45:07 PM
Status update03/14/2023 8:45:07 PM
Last indexation08/29/2023 8:21:34 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack